nMARQ Pulmonary Vein Isolation System for the Treatment of Paroxysmal Atrial Fibrillation

nMARQ Pulmonary Vein Isolation System for the Treatment of Paroxysmal Atrial Fibrillation

Brief description of study

Subjects with symptomatic PAF who have had at least one AF episode documented within one (1) year prior to enrollment and who have failed at least one antiarrhythmic drug (AAD). The Main Study will consist of a prospective, multi-center, randomized (1:1 concurrent nMARQ Catheter System [nMARQ] vs THERMOCOOL® Navigational Family of catheters [TC]), controlled, two-arm, single-blind design. Embedded within the Main Study will be a Subpopulation Neurological Assessment (SNA) with a prospective, controlled design, with consecutive enrollment.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions:
    Atrial Fibrillation, atrial fibrillation
  • Age: Between 1 Years - 99 Years
  • Gender: All
Updated on 07 Sep 2022. Study ID: 817909

Interested in the study

Select a study center that’s convenient for you, and get in touch with the study team.

Contact a study center